Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14472-14487

  Zhao, Chengguang ^a,b,c   Xiao, Hui ^b   Wu, Xiaojuan ^b   Li, Chenglong ^d   Liang, Guang ^c   Yang, Shulin ^a   Lin, Jiayuh ^b  

^a NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Colon cancer; K ras; MEK inhibitor; Pancreatic cancer; Stat3

Indexed keywords

STAT3 PROTEIN; TRAMETINIB; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COLON CANCER; DRUG EFFICACY; DRUG RESPONSE; IN VITRO STUDY; ONCOGENE K RAS; PANCREAS CANCER; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; GENETICS; HUMAN; METABOLISM; ONCOGENE RAS; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENES, RAS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84931063726     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3991     Document Type: Article

References (70)

1. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol. 2009;7: 45-53, 64.
2. Van Der Hoeven D, Cho KJ, Ma X, Chigurupati S, Parton RG, Hancock JF. Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission. Mol Cell Biol. 2013;33: 237-251.
3. Forrester K, Almoguera C, Han KY, Grizzle WE, Perucho M. Detection of High-Incidence of K-Ras Oncogenes during Human-Colon Tumorigenesis. Nature. 1987;327: 298-303.
4. Moon BS, Jeong WJ, Park J, Kim TI, Min DS, Choi KY. Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/beta-Catenin Signaling. J Natl Cancer Inst. 2014;106: djt373.
5. Smit VTHBM, Boot AJM, Smits AMM, Fleuren GJ, Cornelisse CJ, Bos JL. Kras Codon-12 Mutations Occur Very Frequently in Pancreatic Adenocarcinomas. Nucleic Acids Res. 1988;16: 7773-7782.
6. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most Human Carcinomas of the Exocrine Pancreas Contain Mutant C-K-Ras Genes Cell. 1988;53: 549-554.
7. Wei S, Liang Z, Gao J, Wu S, Zhu H, Liu H, Liu T. Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing. J Gastroen Hepatol. 2005;20: 67-72.
8. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN. K-Ras and P53 Gene-Mutations in Pancreatic-Cancer-Ductal and Nonductal Tumors Progress through Different Genetic Lesions. Cancer Res. 1994;54: 1556-1560.
9. Matos P, Oliveira C, Velho S, Gonçalves V, da Costa LT, Moyer MP, Seruca R, Jordan P. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology. 2008;135: 899-906.
10. Sasaki M, Sugio K, Sasazuki T. K-Ras Activation in Colorectal Tumors from Patients with Familial Polyposis-Coli. Cancer. 1990;65: 2576-2579.
11. Bos JL. Ras Oncogenes in Human Cancer-a Review. Cancer Res. 1989;49: 4682-4689.
12. Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer. Gene Chromosome Canc. 2011;50: 307-312.
13. Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 2005;65: 1244-1250.
14. Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, Nishiyama Y, Sato C, Muraoka S, et al. In silico discovery of smallmolecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. P Natl Acad Sci USA. 2013;110: 8182-8187.
15. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503: 548-551.
16. Young A, Lyons J, Miller AL, Phan VT, Alarcon IR, McCormick F. Ras signaling and therapies. Adv Cancer Res. 2009;102: 1-17.
17. Surade S, Blundell TL. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem Biol. 2012;19: 42-50.
18. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011;10: 351-364.
19. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71: 5020-5029.
20. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3: 11-22.
21. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 2007;67: 2098-2106.
22. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14: 1351-1356.
23. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, et al. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. P Natl Acad Sci USA. 2009;106: 18351-18356.
24. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22: 4456-4462.
25. Watanabe M, Sowa Y, Yogosawa M, Sakai T. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci. 2013;104: 687-693.
26. Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y. Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212. Mol Cancer Ther. 2012;11: 720-729.
27. Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metast Rev. 2013;32: 147-162.
28. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drug. 2012;30: 1216-1223.
29. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8: 945-54.
30. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19: 6613-6626.
31. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell. 1999;98: 295-303.
32. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3-A pivotal target for individualized treatment of cancer. Cell Cycle. 2005;4: 1131-1133.
33. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res. 2005;65: 5828-5834.
34. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, Rosewicz S. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 2003;125: 891-905.
35. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22: 319-329.
36. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschläger P, Schütz A, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005;7: 545-555.
37. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J. STAT3 is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells. Cancer Res. 2011;71: 7226-7237.
38. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines-Inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005;167: 969-980.
39. Klampfer L. The role of signal transducers and activators of transcription in colon cancer. Front Biosci-Landmrk. 2008;13: 2888-2899.
40. Lassmann S, Schuster I, Walch A, Göbel H, Jütting U, Makowiec F, Hopt U, Werner M. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol. 2007;60: 173-179.
41. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005;58: 833-838.
42. Lee J Y, Hennighausen L. The transcription factor Stat3 is dispensable for pancreatic beta-cell development and function. Biochem Bioph Res Co. 2005;334: 764-768.
43. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 2006;15: 1445-1451.
44. Huang C, Cao J, Huang KJ, Zhang F, Jiang T, Zhu L, Qiu ZJ. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci. 2006;97: 1417-1423.
45. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li PK, Li C, Fuchs J, et al. Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells. Cancer Res. 2010;70: 2445-2454.
46. Glienke W, Hausmann E, Bergmann L. Downregulation of STAT3 signaling induces apoptosis but also promotes antiapoptotic gene expression in human pancreatic cancer cell lines. Tumor Biol. 2011;32: 493-500.
47. Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J. A Novel Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Activities and Exhibits Potent Growth-Suppressive Activity in Human Cancer Cells. Neoplasia. 2010;12: 39-50.
48. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP. Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells. Cancer Res. 2009;69: 5876-5884.
49. Fan Y, Zhang YL, Wu Y, Zhang W, Wang YH, Cheng ZM, Li H. Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells. World J Gastroentero. 2008;14: 428-434.
50. Metro G, Chiari R, Baldi A, De Angelis V, Minotti V, Crino L. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. Future Oncol. 2013;9: 167-177.
51. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogenactivated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995;270: 27489-27494.
52. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, et al. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. J Clin Oncol. 2013;31: 482-489.
53. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New Engl J Med. 2012;367: 107-114.
54. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013;3: 158-167.
55. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19: 2548-2556.
56. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, et al. Emerging MEK inhibitors. Expert Opin Emerg Drugs. 2010;15: 203-223.
57. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget. 2011;2: 135-164.
58. Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han HY. Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells. Clin Cancer Res. 2011;17: 2744-2756.
59. Grivennikov S1, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer cell. 2009;15: 103-113.
60. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada M, Suzuki K, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004;23: 4921-4929.
61. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101: 1535-1542.
62. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6: 27.
63. Zhao Y, Adjei AA. The clinical development of MEK inhibitors, Nature reviews. Clinical oncology. 2014;11: 385-400.
64. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ. Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells. Sci Signal. 2011;4: ra17.
65. Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2014;21:396-404.
66. Huang G, Yan H, Ye S, Tong C, Ying QL. STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse ESC fates. Stem Cells. 2014;32:1149-1160.
67. Yu W, Xiao H, Lin J, Li C. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 2013;56: 4402-4412.
68. Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J. A Novel Small Molecular STAT3 Inhibitor, LY5 Inhibits Cell Viability, Cell Migration, And Angiogenesis in Medulloblastoma Cells. J Biol Chem. 2015;290:3418-3429.
69. Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogeneaddicted cancer cells. Cancer cell. 2014;26: 207-221.
70. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 2014;7: 1940-1955.